Matthew Durdy, chief executive of the Cell and Gene Therapy Catapult (CGT Catapult), has announced his intention to retire in June 2027, following almost 15 years with the organisation, including seven years leading it.

Since its establishment in 2012, CGT Catapult has played a central role in developing the UK's advanced therapies sector, helping to build the infrastructure, manufacturing capabilities and partnerships needed to translate cell and gene therapy research into treatments for patients.

Reflecting on his decision, Durdy said his time at the organisation had been the privilege of his career, describing the transformation of the UK sector since its foundation.

“When I joined the Catapult at its inception, the UK had world-class science but no real industry to match it. Today, we have both – we have patients receiving therapies, developed and manufactured here, that would have been impossible a decade ago,” he said.

He emphasised the collective effort behind that progress, acknowledging the contribution of Catapult colleagues, NHS partners, academia, Innovate UK, industry and the patient community.

“None of that is mine; it has been the work of an extraordinary team across the Catapult,” he said. “I am proud of what we have built together, and I remain fully committed to the organisation and its mission over the coming months.”

CGT Catapult chair Jim Faulkner described Durdy as a defining figure in the development of the UK's advanced therapies industry.

“Under his leadership, the Cell and Gene Therapy Catapult has grown into one of the most respected institutions of its kind, and the UK now has a cell and gene therapy industry that can compete internationally because of the choices he and his team have made,” Faulkner said.

He added that the board would begin the search for a successor with confidence in the strength of the organisation Durdy had helped build, and would work with him to ensure a seamless transition.

The board has appointed executive search firm Coulter Partners to assist with the recruitment process. Durdy will remain in post until June 2027.